Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients

Spanoudakis, Emmanouil; Bazdiara, Ioanna; Kotsianidis, Ιoannis; Margaritis, Dimitrios; Goutzouvelidis, Aggelos; Christoforidou, Anna; Tsatalas, Costas; Bourikas, George

doi:10.1007/s00277-008-0650-1

Cited by 14 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,8,[10][11][12][13][14] Our data indicate, however, that decrease in JAK2 V617F allele burden does not correlate with clinical and hematologic response, despite different treatments.…”

Section: Discussioncontrasting

confidence: 55%

“…newly diagnosed and treatment naïve, and had varying molecular responses. [12][13][14] In these studies, median time to at least PMoIR was 12-14 months. Therefore, the lack of a similar response in our patients, treated for a median of 5.6 years, cannot be attributed to inadequate duration of treatment.…”

mentioning

confidence: 92%

“…8 In comparison, we reported that in 25 patients treated with recombinant interferon-alpha-2b (rIFNα-2b), only 4 (16%) had a partial molecular response despite excellent clinical and hematologic responses after a median duration of follow up of one year (range 0.1-3.6 years). 9 The effect of various non-interferon treatments on the JAK2 V617F allele burden in PV has also been ambiguous, with some showing significant molecular responses [10][11][12][13][14] and others not. [15][16][17] The well-characterized hematologic responses in patients with PV treated with imatinib showed no significant molecular responses.…”

Section: Introductionmentioning

confidence: 99%

“…The median dose of HU used in our patients was similar to those studies reporting substantial molecular response. [12][13][14] Like interferon, the variability of response to HU may reflect individual differences in drug metabolism and/or disease heterogeneity related to other genetic and molecular factors, as previously mentioned. 26 Although we and others have reported significant hematologic and clinical responses in imatinib-treated patients, 18,19 none reported significant molecular responses, as confirmed in 75% of our imatinib-treated patients who had a hematologic response.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera

Kuriakose

Vandris²,

Wang³

et al. 2011

Haematologica

View full text Add to dashboard Cite

“…7,8,[10][11][12][13][14] Our data indicate, however, that decrease in JAK2 V617F allele burden does not correlate with clinical and hematologic response, despite different treatments.…”

Section: Discussioncontrasting

confidence: 55%

mentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera

Kuriakose

Vandris²,

Wang³

et al. 2011

Haematologica

View full text Add to dashboard Cite

“…4 The hematologic and molecular responses to recombinant interferon alpha (rIFNα) and hydroxyurea (HU) in PV have been characterized. [5][6][7][8] Sustained molecular responses following pegylated-rIFNα therapy have been observed by some clinicians 5,6 but not by others. 8 Similar variability in molecular response has been observed with HU.…”

mentioning

confidence: 99%

JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug

et al. 2013

View full text Add to dashboard Cite

Polycythemia vera: gender-related phenotypic differences

et al. 2011

View full text Add to dashboard Cite

In polycythemia vera, gender has recently been shown to influence the JAK2(V617F) allele burden, but its effect on the disease phenotype is unknown. This issue was investigated using the database of the European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Study. The ECLAP Study recruited 1,638 polycythemic subjects and followed for 2.7 ± 1.3 years. At study entry, men, compared to women, had a higher prevalence of myocardial infarction (11.3 vs. 5.8%; P < 0.0001) and peripheral arterial disease (6.1 vs. 2.9%; P < 0.05) while a history of venous thrombosis was more common in women (11.4 vs. 7.9%, P = 0.016). Among 234 venous thrombosis, there were 39 splanchnic vein thromboses (33 extra-hepatic portal vein thromboses and 6 Budd-Chiari syndromes). Most of these events occurred as an early disease presentation in young female subjects. Women, compared to men, had higher platelet counts (average value 430 ± 213 vs. 375 ± 201 × 10(9)/L; P < 0.0001) and lower hematocrits (0.46 ± 0.06 vs. 0.48 ± 0.06 l/l; P < 0.0001). Cholesterol plasma level, available in 995 subjects (61%), was lower in male patients (180.8 ± 43.1 vs. 196 ± 46.6 mg/dl; P < 0.0001). During follow-up there were 205 major thromboses confirming an high incidence of myocardial infarction in men although not statistically significant (1.2 vs. 0.6 cases per 100 person-years; P > 0.05). These data show several gender-related differences both in the thrombotic diathesis and in the prevalence of vascular risk factors of PV patients.

show abstract

Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients

Cited by 14 publications

References 14 publications

Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera

Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera

JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug

Polycythemia vera: gender-related phenotypic differences

Contact Info

Product

Resources

About